Dupixent dupilumab

The single highest-leverage commercial moment is the first 8 weeks: patients who clear the injection anxiety barrier and survive the co-pay shock report transformative outcomes, while those who stumble at either hurdle abandon before therapeutic benefit materializes.

• Efficacy sentiment is overwhelmingly positive across atopic dermatitis, asthma, COPD, and EoE, with patients using words like 'life-changing' and 'miracle' at unusually high frequency for a chronic-disease biologic.
• Eye-related side effects (conjunctivitis, keratitis, blepharitis) are the single most cited safety concern and the leading driver of early discontinuation in the eczema segment, yet many patients say pro-active ophthalmology co-management resolves the issue.
• Cost and insurance prior-authorization friction dominate pre-treatment anxiety and represent a distinct abandonment window, even for commercially insured patients who later discover the MyWay co-pay program covers most out-of-pocket exposure.
• Self-injection fear is a universal first-time barrier that experienced peers routinely dissolve within one conversation by sharing practical tips (syringe vs. pen, warming technique, slow injection), pointing directly to peer-mentorship as a high-ROI patient-services investment.